AEON Biopharma develops ABP-450 (prabotulinumtoxinA) as a proposed biosimilar to BOTOX (onabotulinumtoxinA) for therapeutic indications. Company announcements focus on analytical similarity work, FDA biosimilar pathway interactions, scientific presentations, and the regulatory strategy supporting ABP-450 development.
Recurring AEON updates also address operating and financial results, liquidity and going-concern disclosures, shareholder meeting matters, inducement equity awards, executive and governance changes, capital-structure actions, and NYSE American continued-listing compliance.
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of AEON Biopharma (AEON)?
AEON Biopharma (AEON) last closed at $0.1230.
What is the market cap of AEON Biopharma (AEON)?
The market cap of AEON Biopharma (AEON) is approximately $10.3M.